Publication | Open Access
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
14
Citations
0
References
2020
Year
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.